乙醯胺酚 IV 市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

2024年全球乙醯胺酚IV市場價值為8.607億美元，預計2025年至2034年將以4.2%的年複合成長率(CAGR)成長。口服藥物時。它對於治療術後恢復、嚴重感染以及患有胃腸道併發症的患者特別有效。

醫院環境對快速止痛的需求，特別是術後和創傷護理，是推動市場成長的關鍵因素。由於成癮和其他副作用的風險，越來越多的患者尋求鴉片類藥物的替代品，非鴉片類止痛藥物（如乙醯胺酚 IV）的受歡迎程度激增。它能夠有效緩解疼痛，同時最大限度地減少副作用，使其成為各種臨床環境的首選。

乙醯胺酚 IV 通常在醫院和診所用於控制中度至重度疼痛，並在口服或直腸藥物不適合時退燒。它是多模式鎮痛方案的關鍵組成部分，特別是在手術環境中，它在減少對鴉片類鎮痛藥的需求和限制鴉片類藥物相關併發症的風險方面發揮著至關重要的作用。

市場分為兩個主要應用類別：手術和非手術。由於乙醯胺酚 IV 在術後疼痛管理的使用不斷增加，手術部分在 2024 年佔據了最大佔有率。由於人口老化和慢性病的流行，全球手術數量不斷增加，進一步支持了這一領域的成長。

在醫療適應症方面，乙醯胺酚靜脈注射市場分為疼痛管理和退燒（發燒）。疼痛管理佔據最大佔有率，受益於在術後護理、急診室和創傷護理中擴大採用非鴉片類藥物替代品來緩解疼痛。向更安全的疼痛管理策略的轉變顯著促進了細分市場的成長。

市場也按最終用途進行細分，其中醫院和診所是主導類別。這些設定受益於乙醯胺酚 IV 提供的快速作用和受控劑量，這使其成為治療急性疼痛和術後恢復的理想選擇。外科手術數量的增加以及對有效疼痛管理解決方案的更加關注預計將推動該領域的持續成長。

2024年，由於對有效疼痛管理的需求不斷增加，特別是在手術和術後護理方面，美國在北美乙醯胺酚靜脈注射市場佔據了很大佔有率。美國市場的成長得益於手術數量的增加、非鴉片類止痛藥的日益普及以及領先製藥公司在該地區的強大影響力。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 疼痛和發燒的盛行率上升
    • 外科手術數量不斷增加
    • 靜脈給藥的優點
    • 重症監護環境中越來越多的採用
  • 產業陷阱與挑戰
    • 與口服替代品相比成本較高
    • 副作用和健康風險
• 成長潛力分析
• 監管環境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按應用分類，2021 - 2034 年

• 主要趨勢
• 外科
• 非手術

第 6 章：市場估計與預測：按指標分類，2021 - 2034 年

• 主要趨勢
• 疼痛管理
• 發熱

第 7 章：市場估計與預測：按最終用途，2021 - 2034 年

• 主要趨勢
• 醫院和診所
• 門診手術中心 (ASC)
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2034

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 9 章：公司簡介

• AdvaCare Pharma
• Altan Pharma
• B. Braun SE
• Cipla Inc.
• Criticine Care
• Fresenius Kabi
• GNova Biotech
• Lupin
• Mallinckrodt Pharmaceuticals
• Pfizer
• Solitaire Pharmacia
• Unital Pharmaceuticals

The Global Paracetamol IV Market was valued at USD 860.7 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2034. Paracetamol IV, known for its strong analgesic and antipyretic properties, is widely used when oral medication is not an option. It is especially effective in managing post-surgical recovery, severe infections, and for patients with gastrointestinal complications.

The demand for fast-acting pain relief in hospital settings, particularly for post-operative and trauma care, is a key factor driving the market growth. As more patients seek alternatives to opioids due to the risks of addiction and other side effects, the popularity of non-opioid pain treatments, such as paracetamol IV, has surged. Its ability to provide effective pain relief while minimizing adverse effects has made it a preferred choice in various clinical settings.

Paracetamol IV is commonly used in hospitals and clinics to manage moderate to severe pain and reduce fever when oral or rectal medications are not suitable. It is a key component of multimodal analgesia protocols, particularly in surgical settings, where it plays a crucial role in reducing the need for opioid-based analgesics and limiting the risk of opioid-related complications.

The market is divided into two primary application categories: surgical and non-surgical. The surgical segment accounted for the largest share in 2024, driven by the growing use of paracetamol IV in post-operative pain management. The increasing number of surgeries worldwide, fueled by a rising aging population and the prevalence of chronic diseases, further supports the growth of this segment.

In terms of medical indications, the paracetamol IV market is split into pain management and fever reduction (pyrexia). Pain management holds the largest share, benefiting from the growing adoption of non-opioid alternatives for pain relief in post-operative care, emergency rooms, and trauma care. The shift toward safer pain management strategies has significantly boosted segment growth.

The market is also segmented by end-use, with hospitals and clinics being the dominant category. These settings benefit from the rapid action and controlled dosage provided by paracetamol IV, which makes it an ideal choice for managing acute pain and post-surgical recovery. The increasing number of surgical procedures and a greater focus on effective pain management solutions are expected to drive continued growth in this segment.

In 2024, the U.S. held a substantial share of the North America paracetamol IV market, driven by an increased demand for efficient pain management, particularly in surgical and post-operative care. The market growth in the U.S. is supported by a rise in the number of surgeries, the growing adoption of non-opioid pain relief, and the strong presence of leading pharmaceutical companies in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of pain and fever
    • 3.2.1.2 Growing number of surgical procedures
    • 3.2.1.3 Advantages of intravenous administration
    • 3.2.1.4 Growing adoption in critical care settings
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost compared to oral alternatives
    • 3.2.2.2 Side effects and health risks
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Surgical
• 5.3 Non-surgical

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Pyrexia

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory Surgical Centers (ASCs)
• 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AdvaCare Pharma
• 9.2 Altan Pharma
• 9.3 B. Braun SE
• 9.4 Cipla Inc.
• 9.5 Criticine Care
• 9.6 Fresenius Kabi
• 9.7 GNova Biotech
• 9.8 Lupin
• 9.9 Mallinckrodt Pharmaceuticals
• 9.10 Pfizer
• 9.11 Solitaire Pharmacia
• 9.12 Unital Pharmaceuticals